|
KMID : 0360220200610030250
|
|
Journal of the Korean Ophthalmological Society
2020 Volume.61 No. 3 p.250 ~ p.257
|
|
|
Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy
|
|
Chung Sae-Rom
Jeong Jin-Gu
Lee Tae-Eun
You In-Cheon
Ahn Min
Cho Nam-Chun
|
|
|
Abstract
|
|
|
Purpose: To evaluate the effect of oral spironolactone for non-resolving chronic central serous chorioretinopathy after intravitreal bevacizumab injection.
Methods: Seventeen eyes of 17 patients with non-resolving chronic central serous chorioretinopathy after intravitreal bevacizumab injection from September 2017 to December 2018 were treated with oral spironolactone for 6 months, and changes in central macular thickness, subretinal fluid height, and best-corrected visual acuity (BCVA) were analyzed retrospectively.
Results: The central macular thickness decreased from 309.94 ± 105.20 μm at baseline to 259.76 ± 81.83 μm at 3 months, and 243.11 ± 61.98 μm at 6 months, which were both statistically significant (Wilcoxon signed-rank test, p = 0.016 and p = 0.001, respectively). The subretinal fluid height decreased from 138.05 ± 95.69 μm at baseline to 70.88 ± 83.13 μm at 3 months, and 54.00 ± 56.25 μm at 6 months, which were both statistically significant (Wilcoxon signed-rank test, p = 0.002 and p = 0.000, respectively). The BCVA (LogMAR) changed from 0.30 ± 0.38 at baseline to 0.35 ± 0.43 at 1 month, 0.29 ± 0.43 at 3 months, and 0.26 ± 0.40 at 6 months. The results at 6 months were statistically significant (Wilcoxon signed-rank test, p = 0.033). There were no side effects in patients treated with oral spironolactone.
Conclusions: In chronic central serous chorioretinopathy, treatment with oral spironolactone significantly reduced the central macular thickness, subretinal fluid height, and the BCVA, without side effects.
|
|
|
KEYWORD
|
|
|
Bevacizumab, Central serous chorioretinopathy, Spironolactone
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|